When all four highly heterogeneous studies were excluded, the OR adjusted to 18.70 (95% CI: 14.77–23.40; p = 0.16), indicating reduced precision but still suggesting a favorable trend toward renal benefit with TAF.
← all excerpts
Improvement in kidney function in patients with chronic hepatitis B and chronic kidney disease after switching to tenofovir alafenamide fumarate: a systematic review with single arm meta-analysis.
1
—
—